mcIRBP-9

mcIRBP-9 is a gastro-resistant bioactive peptide derived from the protease digestion of mcIRBP, an insulin receptor-binding protein isolated from Momordica charantia (bitter melon)[1][5][9]. It consists of 9 amino acids and exhibits potent hypoglycemic activity. mcIRBP-9 enhances insulin receptor kinase activity, activates downstream insulin receptor signaling pathways, promotes phosphorylation of the insulin receptor, induces glucose transporter 4 (GLUT4) translocation, and increases glucose uptake into cells[1][5]. In preclinical models, both intraperitoneal and oral administration of mcIRBP-9 improved glucose tolerance and lowered HbA1c and fasting blood glucose in streptozotocin-induced diabetic mice[1][2][5][9]. The peptide displays unique gastric stability, permitting oral administration. In mouse models of diabetic nephropathy, oral mcIRBP-9 reduced renal vascular leakage and histopathological damage, suggesting additional renoprotective effects in diabetes complications[2]. mcIRBP-9 may achieve its effects both independently and synergistically with endogenous insulin, by binding insulin receptor sites different from native insulin, and potentiating insulin signal transduction[5].